Gmax Biopharm LLC

Gmaz Biopharm LLC

Chenjiang Yao

Hua Zhang

Cheng Zhang

Xiaofeng Wang

Shuqian Jing

Yan Jiang

Min Wang

Xinxin Shi

Hao Pan

Liangliang Bi

Rongzhu Wang

Lei Sun

Provided herein are an apelin receptor (APJ) antibody and its fusion protein with Elabela. Also provided herein is a pharmaceutical composition of a fusion protein with APJ antibody and Elabela, and use thereof in treating, preventing, or alleviating one or more symptoms of pulmonary arterial hypertension, pulmonary hypertension or one or more symptoms of heart failure.

APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01

Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.

GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof

The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.

Human endothelin receptor antibody and use thereof

Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.

GCGR antibody and GLP-1 fusion protein thereof, pharmaceutical composition thereof and application thereof

Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.

Antibody specifically binding to GLP-1R and fusion protein thereof with GLP-1

Antibody specifically binding to GLP-1 R and fusion protein thereof with GLP-1

Growing community of inventors

Hangzhou, China

Chenjiang Yao